Document is current
Any future updates will be listed below
-
Authors
Govindan, Ramaswamy
Aggarwal, Charu
Antonia, Scott J
Davies, Marianne
Dubinett, Steven M
Ferris, Andrea
Forde, Patrick M
Garon, Edward B https://orcid.org/0000-0001-7077-8801
Goldberg, Sarah B
Hassan, Raffit
Hellmann, Matthew D https://orcid.org/0000-0002-2670-9777
Hirsch, Fred R
Johnson, Melissa L
Malik, Shakun
Morgensztern, Daniel
Neal, Joel W
Patel, Jyoti D
Rimm, David L https://orcid.org/0000-0001-5820-4397
Sagorsky, Sarah
Schwartz, Lawrence H
Sepesi, Boris
Herbst, Roy S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02409342 at ClinicalTrials.govnct02477826 at ClinicalTrials.govDocuments that mention this clinical trial
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0606
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA
https://doi.org/10.1136/bmjopen-2023-083716
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02220894 at ClinicalTrials.govDocuments that mention this clinical trial
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
https://doi.org/10.1200/jco.22.01503
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct01905657 at ClinicalTrials.govDocuments that mention this clinical trial
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.363
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
https://doi.org/10.1200/jco.21.02885
nct03088540 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
https://doi.org/10.1016/j.lungcan.2015.02.007
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02409342 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
https://doi.org/10.1200/jco.2023.41.6_suppl.tps284
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.9028
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
https://doi.org/10.1200/jco.2023.41.16_suppl.9022
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
https://doi.org/10.1136/jitc-2023-sitc2023.0600
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02142738 at ClinicalTrials.govDocuments that mention this clinical trial
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0606
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA
https://doi.org/10.1136/bmjopen-2023-083716
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct03088540 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
4CPS-120 Efficacy of pembrolizumab for non-small cell lung cancer (NSCLC): preliminary real-world analysis and comparison with the pivotal study (PS)
https://doi.org/10.1136/ejhpharm-2024-eahp.224
nct02477826 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
https://doi.org/10.1200/jco.2023.41.6_suppl.tps284
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.9028
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
https://doi.org/10.1200/jco.2023.41.16_suppl.9022
600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1
https://doi.org/10.1136/jitc-2023-sitc2023.0600
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02220894 at ClinicalTrials.govDocuments that mention this clinical trial
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
https://doi.org/10.1200/jco.22.01503
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct01905657 at ClinicalTrials.govDocuments that mention this clinical trial
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.363
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
https://doi.org/10.1200/jco.21.02885
nct02366143 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
https://doi.org/10.1016/j.lungcan.2015.02.007
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02367781 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial
https://doi.org/10.1136/jitc-2021-003027
nct02008227 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct03215706 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0584
435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578
26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046
Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC
https://doi.org/10.1136/jitc-2025-013098
28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology
https://doi.org/10.1136/jitc-2021-sitc2021.028
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1090 Cross-cancer immunotherapy response prediction with the CURE AI foundation model
https://doi.org/10.1136/jitc-2025-sitc2025.1090
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607
831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
https://doi.org/10.1136/jitc-2020-001882
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231
nct01642004 at ClinicalTrials.govDocuments that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
https://doi.org/10.1200/jco.2024.42.16_suppl.8560
Tracking the tail
https://doi.org/10.1136/jitc-2020-000971
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
https://doi.org/10.1136/jitc-2023-008189
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9023
nct01673867 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02578680 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02775435 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
https://doi.org/10.1200/jco.22.01989
nct02125461 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
https://doi.org/10.1200/jco.22.01990
nct02142738 at ClinicalTrials.govDocuments that mention this clinical trial
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
https://doi.org/10.1136/ijgc-2019-001135
558 A systematic review of anti-drug antibodies related to CTLA-4, PD-1 or PD-L1 inhibitors across tumour types
https://doi.org/10.1136/jitc-2023-sitc2023.0558
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
nct02409342 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
4CPS-120 Efficacy of pembrolizumab for non-small cell lung cancer (NSCLC): preliminary real-world analysis and comparison with the pivotal study (PS)
https://doi.org/10.1136/ejhpharm-2024-eahp.224
nct02477826 at ClinicalTrials.govDocuments that mention this clinical trial
606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy
https://doi.org/10.1136/jitc-2023-sitc2023.0606
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA
https://doi.org/10.1136/bmjopen-2023-083716
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02220894 at ClinicalTrials.govDocuments that mention this clinical trial
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1186/s12967-023-04705-3
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
https://doi.org/10.1200/jco.22.01503
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02142738 at ClinicalTrials.govDocuments that mention this clinical trial
363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.363
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
https://doi.org/10.1200/jco.21.02885
nct01295827 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
4CPS-120 Efficacy of pembrolizumab for non-small cell lung cancer (NSCLC): preliminary real-world analysis and comparison with the pivotal study (PS)
https://doi.org/10.1136/ejhpharm-2024-eahp.224
nct01905657 at ClinicalTrials.govDocuments that mention this clinical trial
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
https://doi.org/10.1136/jitc-2020-000705
Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://doi.org/10.1016/j.ygyno.2015.02.019
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
https://doi.org/10.1016/s0140-6736(14)60958-2
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02578680 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
https://doi.org/10.1016/j.lungcan.2015.02.007
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
nct02775435 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
https://doi.org/10.1136/jitc-2021-sitc2021.364
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
https://doi.org/10.1200/jco.22.01989
nct02366143 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
https://doi.org/10.1200/jco.22.01990
nct02367781 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial
https://doi.org/10.1136/jitc-2021-003027
nct03215706 at ClinicalTrials.govDocuments that mention this clinical trial
30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
https://doi.org/10.1136/esmoopen-2017-000298
1197 Harnessing the cancer immunity cycle via machine learning models to generate novel strategies for personalized cancer therapy
https://doi.org/10.1136/jitc-2024-sitc2024.1197
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02008227 at ClinicalTrials.govDocuments that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
https://doi.org/10.1200/jco.2024.42.16_suppl.8560
Tracking the tail
https://doi.org/10.1136/jitc-2020-000971
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
https://doi.org/10.1136/jitc-2023-008189
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9023
nct01642004 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0584
435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578
26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046
Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC
https://doi.org/10.1136/jitc-2025-013098
28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology
https://doi.org/10.1136/jitc-2021-sitc2021.028
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1090 Cross-cancer immunotherapy response prediction with the CURE AI foundation model
https://doi.org/10.1136/jitc-2025-sitc2025.1090
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607
831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
https://doi.org/10.1136/jitc-2020-001882
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231
nct01673867 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02125461 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy in the treatment of non-small cell lung cancer
https://doi.org/10.1016/j.lungcan.2014.05.005
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02763579 at ClinicalTrials.govDocuments that mention this clinical trial
CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study
https://doi.org/10.1136/ijgc-2019-001135
558 A systematic review of anti-drug antibodies related to CTLA-4, PD-1 or PD-L1 inhibitors across tumour types
https://doi.org/10.1136/jitc-2023-sitc2023.0558
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
nct03043872 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02763579 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
586 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN
https://doi.org/10.1136/jitc-2022-sitc2022.0586
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8516
nct03043872 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct03066778 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
586 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in extensive-stage small-cell lung cancer (ES–SCLC): RNA sequencing analysis to explore canonical markers of IO activity in CASPIAN
https://doi.org/10.1136/jitc-2022-sitc2022.0586
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
The prognostic value of patient reported outcomes (PROs) and clinical/demographic variables in the CASPIAN study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8516
nct03382561 at ClinicalTrials.govDocuments that mention this clinical trial
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.
https://doi.org/10.1200/jco.2023.41.16_suppl.8503
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct01928394 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct02054806 at ClinicalTrials.govDocuments that mention this clinical trial
Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
https://doi.org/10.1136/jitc-2023-007883
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
https://doi.org/10.1016/j.ejca.2016.02.020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Development of molecularly targeted agents and immunotherapies in small cell lung cancer
https://doi.org/10.1016/j.ejca.2016.03.004
Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
https://doi.org/10.1136/jitc-2025-013222
nct02628067 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
https://doi.org/10.1136/ijgc-2019-001012
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Phase 2 study of pembrolizumab in patients with advanced rare cancers
https://doi.org/10.1136/jitc-2019-000347
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
https://doi.org/10.1136/jitc-2021-003091
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
https://doi.org/10.1136/thoraxjnl-2017-211416
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct02899299 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
https://doi.org/10.1136/jitc-2023-007440
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
https://doi.org/10.1136/jitc-2020-000564
Targeted therapy in cervical cancer
https://doi.org/10.1136/esmoopen-2018-000462
Combined modality management of advanced cervical cancer including novel sensitizers
https://doi.org/10.1136/ijgc-2021-003137
41 External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS ≥ 1 and CPS ≥ 10
https://doi.org/10.1136/jitc-2022-sitc2022.0041
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.e15137
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
https://doi.org/10.1136/jitc-2020-000785
Combined modality including novel sensitizers in gynecological cancers
https://doi.org/10.1136/ijgc-2021-002529
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis
https://doi.org/10.1007/s12325-025-03142-6
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct03158129 at ClinicalTrials.govDocuments that mention this clinical trial
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
https://doi.org/10.1200/jco-25-01328
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
https://doi.org/10.1136/jitc-2019-000461
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
https://doi.org/10.1136/thoraxjnl-2017-211416
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
https://doi.org/10.1136/jitc-2021-002387
nct02259621 at ClinicalTrials.govDocuments that mention this clinical trial
277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy
https://doi.org/10.1136/jitc-2020-sitc2020.0277
1242 Integrative machine learning for identifying treatment-specific impacts and biomarkers applied to multi-platform data from non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapies
https://doi.org/10.1136/jitc-2024-sitc2024.1242
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
590 Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0590
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2024-009677
962 Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.962
nct03816345 at ClinicalTrials.govDocuments that mention this clinical trial
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.286
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
https://doi.org/10.1136/jitc-2020-001282
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.327
1004 Immune checkpoint blockade unleashes mucosal associated invariant T (MAIT) cells in tumor microenvironment of NSCLC patients
https://doi.org/10.1136/jitc-2023-sitc2023.1004
293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2021-sitc2021.293
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers
https://doi.org/10.1136/jitc-2022-sitc2022.0538
878 The immunomodulatory impact of chemotherapy when combined with PD-1 blockade in resectable lung cancers
https://doi.org/10.1136/jitc-2024-sitc2024.0878
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma
https://doi.org/10.1136/jitc-2021-sitc2021.665
57 CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy
https://doi.org/10.1136/jitc-2022-sitc2022.0057
1255 Longitudinal assessment of the gut microbiome and its association with treatment response in patients with non-small cell lung cancer receiving neoadjuvant immunotherapy
https://doi.org/10.1136/jitc-2024-sitc2024.1255
nct03816332 at ClinicalTrials.govDocuments that mention this clinical trial
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
https://doi.org/10.1136/jitc-2019-000356
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
https://doi.org/10.1136/jitc-2021-002567
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
nct02008227 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients
https://doi.org/10.1136/jitc-2020-000908
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Acute Kidney Injury in Critically Ill Patients with Cancer
https://doi.org/10.2215/cjn.15681221
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers
https://doi.org/10.1200/jco.23.01497
nct03164616 at ClinicalTrials.govDocuments that mention this clinical trial
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy
https://doi.org/10.1136/jitc-2022-005924
Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy
https://doi.org/10.1136/bmjonc-2023-000128
584 Evaluation of a composite immunotherapy signature in non-small cell lung cancer patients treated with atezolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0584
435 Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
https://doi.org/10.1136/jitc-2022-sitc2022.0435
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(16)00587-0
Development and validation of a serum proteomic test for predicting patient outcomes in advanced non-small cell lung cancer treated with atezolizumab or docetaxel
https://doi.org/10.1136/jitc-2024-010578
26 Validation of the Primary Immune Response (PIR) test in advanced non-small cell lung cancer (NSCLC): blinded retrospective analyses from the POPLAR and OAK trials
https://doi.org/10.1136/jitc-2021-sitc2021.026
46 Efficacy of atezolizumab and docetaxel in patients with HER2-positive non-small cell lung cancer: a pooled post hoc of the OAK and POPLAR trials
https://doi.org/10.1136/jitc-2023-sitc2023.0046
Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC
https://doi.org/10.1136/jitc-2025-013098
28 Predictions of outcomes and benefit of immune checkpoint inhibitor treatment in NSCLC require information on both tumor and host biology
https://doi.org/10.1136/jitc-2021-sitc2021.028
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
1090 Cross-cancer immunotherapy response prediction with the CURE AI foundation model
https://doi.org/10.1136/jitc-2025-sitc2025.1090
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab
https://doi.org/10.1136/jitc-2025-013727
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
https://doi.org/10.1136/jitc-2023-006913
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials
https://doi.org/10.1136/jitc-2021-sitc2021.329
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
https://doi.org/10.1136/jitc-2023-008185
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
https://doi.org/10.1136/jitc-2023-007047
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials.
https://doi.org/10.1200/jco.2024.42.16_suppl.2607
831 Exact Shapley values for explaining complex machine learning based molecular tests of checkpoint inhibitors: potential utility for patients, physicians, and translational research
https://doi.org/10.1136/jitc-2021-sitc2021.831
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
https://doi.org/10.1136/jitc-2019-000500
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
https://doi.org/10.1136/jitc-2020-001882
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
https://doi.org/10.1136/jitc-2020-002231
nct03409614 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
https://doi.org/10.1200/jco.22.00975
nct03409614 at ClinicalTrials.govDocuments that mention this clinical trial
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.9028
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct03164616 at ClinicalTrials.govDocuments that mention this clinical trial
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.
https://doi.org/10.1200/jco.2023.41.16_suppl.9028
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
nct03425643 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
https://doi.org/10.1136/jitc-2022-sitc2022.0581
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
https://doi.org/10.1200/jco.22.00975
nct02504372 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba100
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).
https://doi.org/10.1200/jco.2024.42.16_suppl.8012
nct03800134 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
What is the role of surgery in potentially resectable N2 non-small cell lung cancer?
https://doi.org/10.1136/thoraxjnl-2018-212287
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
https://doi.org/10.1136/jitc-2021-002780
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01281-7
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8520
nct04025879 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN.
https://doi.org/10.1200/jco.2024.42.16_suppl.8011
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
nct03703297 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
https://doi.org/10.1136/jitc-2024-009799
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
https://doi.org/10.1136/jitc-2020-002248
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba8007
nct05060016 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba5
Carbon footprint of industry-sponsored late-stage clinical trials
https://doi.org/10.1136/bmjopen-2023-072491
nct03703297 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.
https://doi.org/10.1200/jco.2024.42.16_suppl.8015
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
https://doi.org/10.1007/s40487-025-00372-0
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
https://doi.org/10.1007/s12325-025-03136-4
nct05060016 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
https://doi.org/10.1200/jco.2024.42.17_suppl.lba5
Carbon footprint of industry-sponsored late-stage clinical trials
https://doi.org/10.1136/bmjopen-2023-072491
nct02784171 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)—Efficacy and safety analyzed by presence of brain metastasis.
https://doi.org/10.1200/jco.2024.42.16_suppl.8015
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
https://doi.org/10.1007/s40487-025-00372-0
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial
https://doi.org/10.1007/s12325-025-03136-4
Documents that mention this clinical trial
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956add1
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba8505
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
https://doi.org/10.1136/jitc-2019-000461
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
- License Information
